ライフサイエンスコーパス: intraductal

1 n (n = 27), biliary strictures (n = 10), and intraductal abnormalities (n = 7) was 96.3%, 90%, and 10

2 The presence of dilatation, strictures, and intraductal abnormalities was recorded.

3 Intraductal administration of PLD to neu-N mice caused r

4 ced by i.p. administration of cerulein or by intraductal administration of sodium taurocholate.

5 Intraductal administration resulted in lower circulating

6 l models indicate that PADI4 is critical for intraductal aggregate formation and that PADI4-deficienc

7 e biliary drainage, the beneficial effect of intraductal antibiotic prophylaxis was even more evident

8 Patients profiting most obviously from intraductal antimicrobials were those with secondary scl

9 We found that the intraductal approach is feasible for the study of the ea

10 Our objective was to explore an intraductal approach to studying breast cancer and preca

11 ANP was induced in rats by standardized intraductal bile acid infusion and cerulein hyperstimula

12 after testing, two were found to have occult intraductal breast cancers.

13 overexpression was identified in 22% of pure intraductal breast carcinomas and in 35% of breast CIS w

14 p53 overexpression were relatively common in intraductal breast carcinomas but were not observed in a

15 An analysis was performed of 270 intraductal breast carcinomas in 268 women from 10 insti

16 been identified in breast carcinoma in situ (intraductal breast carcinomas).

17 isease that exists in large-duct (often with intraductal calculi) or small-duct form.

18 We were successful in intraductal cannulation and endoscopy in seven of the ni

19 to mouse submandibular glands is possible by intraductal cannulation and that reduction of either the

20 re increasingly common in patients with pure intraductal carcinoma (DCIS).

21 Foci of intraductal carcinoma could be microdissected from 85 ca

22 ications were associated with more extensive intraductal carcinoma, more Her2/neu immunoreactivity, a

23 neficial than lumpectomy alone for localized intraductal carcinoma-in-situ (DCIS).

24 No LOH was seen in pure intraductal carcinomas (0/20 cases).

25 mas in situ and three low-grade invasive and intraductal carcinomas (2-5 mm).

26 uctal carcinomas, two mixed infiltrating and intraductal carcinomas, two infiltrating lobular carcino

27 For patients </= 55 years old, extensive intraductal component (EIC) was the next significant spl

28 78), and having a tumor without an extensive intraductal component (OR, 2.07; 95% CI, 1.81 to 2.37) w

29 LOH was detected in the intraductal component in 26 of these 30 cases.

30 iation therapy whether there is an extensive intraductal component or not.

31 An associated intraductal component was present in 59% of BABCs and 76

32 ss of Dpc4 expression was associated with an intraductal component which showed focal loss of Dpc4 ex

33 margins of excision, absence of an extensive intraductal component, nodal status, estrogen receptor s

34 ty because of their large size and prominent intraductal component.

35 had invasive ductal carcinoma with extensive intraductal component.

36 or invasive ductal carcinoma with extensive intraductal component.

37 obular cancers, or cancers with an extensive intraductal component.

38 All 79 of the intraductal components of the IPMNs strongly expressed D

39 ed to express specific genes into a "mammary intraductal DCIS" xenograft model.

40 endocrine beta-cells, while local pancreatic intraductal delivery of AAV6 showed the best efficiency

41 l complete response (absence of invasive and intraductal disease in the breast and the axillary lymph

42 mmary tumor virus-EZH2 virgin mice developed intraductal epithelial hyperplasia resembling the human

43 nd colocalization with beta-catenin in human intraductal epithelial hyperplasia, the earliest histolo

44 pancreaticoduodenectomy); all had dysplastic intraductal epithelium and chronic pancreatitis, whereas

45 In five women who had a focal intraductal filling defect, immediate stereotactic vacuu

46 specificity for strictures, dilatation, and intraductal filling defects (all choledocholithiasis) we

47 MRCP images for strictures, dilatation, and intraductal filling defects.

48 Intraductal glyceryl trilinoleate with or without the li

49 iant of bile duct carcinoma characterized by intraductal growth and better outcome compared with the

50 h or without MDE typically exhibit extensive intraductal growth but are slow to invade the periductal

51 ificantly higher than those in IDC, atypical intraductal hyperplasia, and normal breast epithelia adj

52 ed enhanced ductal branching, dilated ducts, intraductal hyperplasia, hyperplastic alveolar nodules a

53 se in lateral ductal branching and pervasive intraductal hyperplasia.

54 elevant doses of BPA increased the number of intraductal hyperplasias and ductal carcinomas in situ b

55 eoplastic foci, LOH occurred in two of eight intraductal hyperplasias but not in histologically norma

56 Microdissected foci of intraductal, infiltrating, and metastatic tumors were an

57 Acute pancreatitis was induced in rats by intraductal infusion of 3.5% sodium taurocholate.

58 njury may be decreased significantly with an intraductal infusion of chilled saline.

59 ctivated duct cells by labeling them through intraductal infusion with a cell-tagging dye, CFDA-SE No

60 th a combination of caerulein and controlled intraductal infusion.

61 ere delivered into the mouse mammary teat by intraductal injection in the absence of surgical manipul

62 CP was induced in Sprague-Dawley rats by an intraductal injection of 2% trinitrobenzene sulfonic aci

63 We evaluated induction of inflammation (by intraductal injection of [(14)C]sucrose and histological

64 Using intraductal injection of a lentivirus to deliver both an

65 Our results demonstrate that intraductal injection of adenovirus vectors provides a v

66 re readily induced to form mammary tumors by intraductal injection of RCAS (an ALV/A-derived vector)

67 designed to replicate the human variables by intraductal injection of the triglyceride glyceryl trili

68 CP was induced by intraductal injection of trinitrobenzene sulfonic acid i

69 CP was induced in rats by intraductal injection of trinitrobenzene sulfonic acid.

70 Compared with systemic administration, intraductal injection provides direct access to breast l

71 Intraductal instillation of an RCAS vector carrying the

72 nvasive neoplastic precursor, the pancreatic intraductal lesion (PIL).

73 ported to result in improved localization of intraductal lesions and may avoid surgery in women with

74 1B), and all 23 atypical papillary (PanIN-2) intraductal lesions expressed Dpc4.

75 Ductoscopy identifies intraductal lesions in a high proportion of women with S

76 ma develops from histologically identifiable intraductal lesions that undergo a series of architectur

77 ne of the seven patients, a benign-appearing intraductal mass was identified at MR imaging; excisiona

78 During progression of prostate cancer, the intraductal microvessel density (IMVD) was also observed

79 IPMNs are intraductal mucin-producing cystic neoplasms of the panc

80 Mucinous (intraductal mucinous neoplasm or mucinous cystic neoplas

81 Pancreatic cysts may be intraductal mucinous neoplasms, mucinous cystic neoplasm

82 Pancreatic intraductal neoplasia (PanIN) is thought to be the precu

83 11 antigen localizes to regions of prostatic intraductal neoplasia in paraffin-embedded sections.

84 small percentage of preneoplastic pancreatic intraductal neoplasia lesions lost rap1GAP expression, w

85 The proportion of women with intraductal neoplasia was slightly greater in the group

86 solid nodules, ductal hyperplasia, and mini-intraductal neoplasm and adenoma.

87 ancreatitis can be reduced experimentally by intraductal neurokinin-1 receptor antagonist and clinica

88 umpectomy specimens to determine presence of intraductal or invasive cancer.

89 ed for the Dpc4 protein (n = 50), all of the intraductal or noninvasive components strongly expressed

90 : A survey of women aged 20 to 79 years with intraductal or stage I and II breast cancer diagnosed be

91 cluding cystic tumors, endocrine tumors, and intraductal pancreatic mucinous neoplasms are included.

92 Experiences of the treatment of intraductal pancreatic mucinous neoplasms shed some ligh

93 s published large series on the treatment of intraductal pancreatic mucinous neoplasms.

94 tumors and the premalignant biliary lesions, intraductal papillary biliary neoplasms (IPBN), and Von

95 ontrol mice developed sporadic, macroscopic, intraductal papillary lesions with histologic and molecu

96 nts (40%), MRI revealed a pancreatic lesion: intraductal papillary mucinous neoplasia (14 patients, 3

97 n the rapid development of tumors resembling intraductal papillary mucinous neoplasia (IPMN), a precu

98 ive parameters predict malignant or invasive intraductal papillary mucinous neoplasia (IPMN).

99 as (mPanIN) and promoted a high incidence of intraductal papillary mucinous neoplasia and active fibr

100 One patient had a synchronous intraductal papillary mucinous neoplasia and pancreatic

101 r pancreatic ductal adenocarcinoma and 2 for intraductal papillary mucinous neoplasia), while the rem

102 BACKGROUND & AIMS: Intraductal papillary mucinous neoplasias (IPMNs) are pr

103 etter for noninvasive compared with invasive intraductal papillary mucinous neoplasm (84.5% vs. 36%;

104 ts (72%) and in small (</=30 mm) branch-duct intraductal papillary mucinous neoplasm (BD IPMN; 67%),

105 l consensus guidelines for the management of intraductal papillary mucinous neoplasm (IPMN) and mucin

106 uidelines for management of branch duct (BD) intraductal papillary mucinous neoplasm (IPMN) espouse s

107 ted with main pancreatic duct (MPD)-involved intraductal papillary mucinous neoplasm (IPMN) has been

108 to malignancy of pancreatic branch-duct (BD) intraductal papillary mucinous neoplasm (IPMN) is infreq

109 and mucin staining were similar to those of intraductal papillary mucinous neoplasm (IPMN) of the pa

110 reatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor

111 Human intraductal papillary mucinous neoplasm (IPMN) specimens

112 Moreover, cystic lesions resembling intraductal papillary mucinous neoplasm (IPMN) were obse

113 arcinoma (PDAC) and its preneoplastic lesion intraductal papillary mucinous neoplasm (IPMN), to find

114 sence of invasive carcinoma in patients with intraductal papillary mucinous neoplasm (IPMN).

115 Intraductal papillary mucinous neoplasm (particularly th

116 premalignant (mucinous cystic neoplasm =16, intraductal papillary mucinous neoplasm = 5, neuroendocr

117 neuroendocrine tumors = 4), or 10 malignant (intraductal papillary mucinous neoplasm = 7, cystadenoca

118 between SCA and premalignant mucinous cysts (intraductal papillary mucinous neoplasm [IPMN], mucinous

119 ssessment of guidelines for the treatment of intraductal papillary mucinous neoplasm and cystic lesio

120 Intraductal papillary mucinous neoplasm and pancreatic n

121 -term survival after resection of pancreatic intraductal papillary mucinous neoplasm and to correlate

122 guidelines for mucinous cystic neoplasm and intraductal papillary mucinous neoplasm are superior to

123 pancreatic surgery, only one patient with an intraductal papillary mucinous neoplasm had high-grade d

124 Intraductal papillary mucinous neoplasm patients appear

125 Invasive intraductal papillary mucinous neoplasm recurs frequentl

126 In contrast, noninvasive intraductal papillary mucinous neoplasm recurs infrequen

127 l benign, whereas mucinous cystic neoplasms, intraductal papillary mucinous neoplasm, cystic neuroend

128 In invasive intraductal papillary mucinous neoplasm, recurrence was

129 e, that Tif1gamma and Smad4 both regulate an intraductal papillary mucinous neoplasm-to-PDAC sequence

130 rmed mainly for neuroendocrine tumors (35%), intraductal papillary mucinous neoplasms (33%), solid ps

131 tic neoplasms (adenoma 28, borderline 7), 22 intraductal papillary mucinous neoplasms (adenoma 9, bor

132 pancreatic cysts, especially for branch duct intraductal papillary mucinous neoplasms (BD-IPMNs), rem

133 s known about the development of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs).

134 a large single-center population of resected intraductal papillary mucinous neoplasms (IPMN) of the p

135 l consensus guidelines for the management of intraductal papillary mucinous neoplasms (IPMN) recommen

136 ogression following resection for pancreatic intraductal papillary mucinous neoplasms (IPMN) using ta

137 (1.8%): 12 pseudocysts, 2 cysts/remnants, 4 intraductal papillary mucinous neoplasms (IPMN), 2 adeno

138 ttle is known about the origin of pancreatic intraductal papillary mucinous neoplasms (IPMN).

139 GNAS-activating mutations are reported in intraductal papillary mucinous neoplasms (IPMNs) and in

140 lly-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and pre

141 Intraductal papillary mucinous neoplasms (IPMNs) are the

142 nsus Guidelines, the diagnostic criterion of intraductal papillary mucinous neoplasms (IPMNs) involvi

143 The molecular pathology of intraductal papillary mucinous neoplasms (IPMNs) of the

144 Intraductal papillary mucinous neoplasms (IPMNs) of the

145 ad use and advances in radiographic imaging, Intraductal Papillary Mucinous Neoplasms (IPMNs) of the

146 inoma may be encountered in association with intraductal papillary mucinous neoplasms (IPMNs) of the

147 Intraductal papillary mucinous neoplasms (IPMNs) of the

148 stic cyst types: serous cystadenomas (SCAs), intraductal papillary mucinous neoplasms (IPMNs), mucino

149 isting management guidelines for branch-duct intraductal papillary mucinous neoplasms (IPMNs).

150 ients with mucinous cystic neoplasms (n=17), intraductal papillary mucinous neoplasms (n=15), serous

151 , including 3 node-negative R0 microinvasive intraductal papillary mucinous neoplasms (without recurr

152 ted neoplasms were identified in 85 HRIs (82 intraductal papillary mucinous neoplasms and 3 pancreati

153 n had high-grade dysplasia in less than 3 cm intraductal papillary mucinous neoplasms and in multiple

154 onitored clinically, mucinous cysts, such as intraductal papillary mucinous neoplasms and mucinous cy

155 More cases of intraductal papillary mucinous neoplasms are being diagn

156 Intraductal papillary mucinous neoplasms are increasingl

157 Intraductal papillary mucinous neoplasms are the most co

158 ctively reviewed and classified 113 resected intraductal papillary mucinous neoplasms as invasive car

159 Intraductal papillary mucinous neoplasms can be multifoc

160 Intraductal papillary mucinous neoplasms of the pancreas

161 l features of invasive carcinomas arising in intraductal papillary mucinous neoplasms of the pancreas

162 (1.9%) had high-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 panc

163 plasms-related tumors (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.

164 Intraductal papillary mucinous neoplasms represent a dis

165 ing cystic tumors (mucinous cystic neoplasms+intraductal papillary mucinous neoplasms) from benign cy

166 had pancreatic ductal adenocarcinoma, 17 had intraductal papillary mucinous neoplasms, 26 had symptom

167 les; we found dMMR in a larger proportion of intraductal papillary mucinous neoplasms-related tumors

168 strategy in the management of patients with Intraductal Papillary Mucinous Neoplasms.

169 2D) oncogene in the mouse pancreas to induce intraductal papillary mucinous neoplasms.

170 s mutations in the pancreas of patients with intraductal papillary mucinous tumors (IPMT) and to anal

171 Intraductal papillary mucinous tumors continue to be com

172 Intraductal papillary mucinous tumors of the pancreas ha

173 Two of 11 intraductal papillary mucinous tumors were positive for

174 of large intraductal stones, localization of intraductal papillary mucinous tumors, and localization

175 y and differentiation between ductal type of intraductal papillary mucinous tumors.

176 Intraductal papillary neoplasm of the bile duct (IPNB) i

177 ience with mucinous ductal ectasia (MDE) and intraductal papillary neoplasms (IPNs) and to compare th

178 Intraductal papillary neoplasms with or without MDE repr

179 Despite the growing awareness of intraductal papillary-mucinous neoplasms (IPMNs) of the

180 Intraductal papillary-mucinous neoplasms (IPMNs) of the

181 Intraductal papillary-mucinous tumor (IPMT) of the pancr

182 rize gene expression profiles in a series of intraductal papillary-mucinous tumors (IPMTs) of the pan

183 The encompessing term intraductal papillary-mucinous tumors is appropriate.

184 Fifty-seven percent were found to have intraductal papilloma as the source of discharge, with f

185 c follow-up showed no residual lesion in 10, intraductal papilloma in 14, intraductal papillomatosis

186 defect was performed; results were a benign intraductal papilloma in each, with atypia in one.

187 enign, and 22 matched those of corresponding intraductal papillomas that were involved by or were sep

188 t of displaced cells, usually originating in intraductal papillomas.

189 l lesion in 10, intraductal papilloma in 14, intraductal papillomatosis in two, papilloma with adjace

190 nomas are thought to arise from noninvasive, intraductal precursor lesions called pancreatic intraepi

191 ed to arise from histologically identifiable intraductal precursors [pancreatic intraepithelial neopl

192 DL, which has been associated with decreased intraductal pressure and fewer bile infarcts.

193 e were mainly observed in areas of intensive intraductal proliferation and high tumor cell density.

194 appropriately viewed as an early neoplastic intraductal proliferation.

195 By exploiting an intraductal retrovirus (RCAS)-mediated gene delivery met

196 Intraductal RFA, via both endoscopic and percutaneous ap

197 s in breast-duct anatomy limit the degree of intraductal spread and explain much of the substantial a

198 n the left hepatic lobe with the presence of intraductal stones and dilatation of intrahepatic ducts.

199 nal chronic pancreatitis, treatment of large intraductal stones, localization of intraductal papillar

200 Intraductal trypsin, in subinflammatory concentrations,

201 ed hyperplasia is reversible until extensive intraductal vascularization occurs, but continued progre

202 phenotype in 3D triple-negative cultures and intraductal xenografts by sustaining expression of E-cad